News & Media

Q2 2017 Update: DBM Sends Delegates to BIO and RESI Conferences in San Diego

As mentioned in the Q1 2017 update, it is an exciting year thus far for DiscoveryBioMed with the acquisition of a BioTek Cytation 5 anchored automated system. In order to market these new capabilities and build new relationships with potential clients and partners, DBM sent a team of delegates to both the BIO International Convention and at RESI (hosted by Life Science Nation) in San Diego this past July.

Last year at BIO 2016, DBM was invited to exhibit at the BIO Innovation Zone with other select companies that are pushing the boundaries on scientific innovation and translation to the marketplace. Last year at the BIO Investor Forum, DBM was sponsored by the NIH NIDDK to present the latest data from our Adiponectin Inducer program.

This year in an effort to further increase DBM’s reach, delegates looked outside the formal BIO convention for additional meetings and attended another conference called RESI. Between these two conventions and over the course of two and a half days, DBM’s delegates Erik Schwiebert, Lawrence Greer, and Matthew Redmann had over 35 meetings with potential clients and future partners. This volume matched the activity at last year’s BIO convention.

DiscoveryBioMed is always expanding its CRO services portfolio. However, its core focus remains tightly rooted in a humanized drug discovery philosophy – meaning utilizing the most relevant humanized cellular platform as possible, regardless of whether that process is for our clients or for our own R&D programs. If you or your company are in need of custom services, especially in renal, respiratory, dermatology and metabolic diseases areas, submit a request through our online store.

Continue Reading »

Q1 2017 Update: DBM Invests in Cytation 5 Anchored Automated System

Discovery BioMed prides itself on utilizing the latest technology platforms and offering services based on these advanced systems. In H1 2017 DBM invested in a BioTek Cytation 5 anchored automatic robotics system supported by BioTek’s BioSpa 8 and a BioTek plate washer. Together this system provides high-content automated fluorescence, luminescence, brightfield imaging and plate reading modalities.

After an initial period of set-up and optimization, DBM is now utilizing this platform for both its CRO services and R&D arms. One service that has proven popular with our large biopharma clients, leverages DBM’s expertise in renal biology and is a demonstration of the types of assays we offer is DBM’s in vitro 3D cyst formation assay. This is assay is directed towards clients and researchers with a principle interest in human renal diseases that exhibit cystogenesis as part of their pathology.

As with all research projects undertaken by DBM, we base the assay on human tissue platforms. This enables greater translatability of the results and a better likelihood of eventual clinical success. This assay in particular relies upon our ethically obtained human normal and autosomal dominant polycystic kidney disease cell platforms. DBM is currently expanding its cryovial repository of these cells with mutations in either PKD1 or PKD2 available as platforms. These primary cells are seeded into Biogels where they form bone fide cysts in culture and can be exposed to therapeutic assets.  Using our robotics line, cyst size can be tracked over several days or weeks. Images can be automatically captured daily and viability measured at the experiments conclusion.

It is important to note that this is just one example and DBM’s CRO arm remains focused on custom assay and platform development.

Continue Reading »

Q4 2016 Update – DBM Participates at BIO’s 2016 International Conference and BIO’s 2016 Investor Forum, Continues an Active Intern Program

In June 2016, DBM’s Dr. Erik Schwiebert and Dr. John Streiff, with support from our long-time consultant, Dr. Douglas Hay, traveled to San Francisco to participate in the annual BIO International Meeting. There, DBM met with over 40 companies within and outside the BIO Partnering Forum. The NIH NIDDK also nominated and supported DBM at the convention with an Exhibit Kiosk in the NIH Innovation Zone. DBM was humbled and grateful for this opportunity. DBM was also an active partner in the BioAlabama exhibit.

Additionally, DBM was nominated by the NIH NDDK to participate in the Annual 2016 Bio Investor forum. And, in October, DBM traveled to San Francisco, once again, to present the results from an in vivo study with lead compounds from its Metabolic R&D program. DBM’s presentation was well received and its presence made possible by an NIDDK administrative supplement to an active SBIR award for registration and travel funds. DBM’s Dr. Schwiebert declared that “DBM continues to be honored and grateful for the deep support from the NIDDK in our partnering and business development efforts.”

Over the past year, DBM has been host to productive and outstanding interns. UAB students Cherie Verbal, Ophelia Johnson, and Albert Nakayama performed active work for DBM part-time from January through August 2016. Albert is continuing work with DBM going forward for the next 6-9 months as nearly full-time employee at present. These outstanding student interns were part of a Master’s program in Biomedical Engineering at UAB focused on Design and Commercialization. DBM is assisting Cherie in finding employment in the Huntsville area, while DBM is supporting in part Ophelia’s time in London where she has a prestigious fellowship in biomedical engineering and commercialization. In addition to this, DBM hosted 9 UAB Ph.D. students in exposure and immersion experiences at DBM and has identified a handful of promising candidates to join us and/or allied companies that we are helping as new startups.

Continue Reading »

DiscoveryBioMed, Inc. Declares a Sharpened Focus on Renal Cell Biology and Physiology and on Renal Diseases

Through both natural evolution of our R&D programs and within our CRO services business, DiscoveryBioMed, Inc. (DBM, Inc.) has identified a sharpening focus in Renal or Kidney Cell Biology and Physiology and in Renal Diseases over the last year, in 2016, and going forward.

We invite interested parties to view our newly redesigned website where this focus is declared and apparent.

It is ironic that DBM’s founder, Dr. Erik Schwiebert, first worked on Renal Cell Physiology while a lab technician, first year Ph.D. student, and Ph.D. candidate while in Dr. Bruce Stanton’s laboratory at Dartmouth. “In my very first memories of culturing rodent and human cells, I was involved in establishing primary cultures and growing those cultures and immortal cell lines from the nephron of the kidney so as to study the regulation of epithelial sodium and chloride channels in collecting duct-derived cells,” Erik explained. “I am very familiar with establishing and growing kidney cells as well as studying them and characterizing them. It is therefore not surprising that DBM has also gravitated to that although it was not overtly intentional.”

Continue Reading »

It is who we are – It is what we do

Since the ‘light bulb idea moment’ in 2006 and the pre-launch and launch periods in 2007, DiscoveryBioMed, Inc. (DBM, Inc.) has held the solid core principle of Humanized Drug Discovery, the use of intact, living human cells in culture as the biologically-relevant and disease-relevant cell platforms on which to perform meaningful small molecule discovery and critical hit-to-lead and lead compound profiling. This core principle holds for both our internal R&D programs and our contract research organization (CRO) services business.

Continue Reading »

DiscoveryBioMed, Inc. is developing a novel and unprecedented “dual action” small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases

DiscoveryBioMed, Inc. (DBM, Inc.), fueled by recent advances in its Respiratory Diseases R&D program, has discovered and is developing a novel class of small molecule monotherapy that affects both major drug targets in CF. Proper function of the two target proteins that serve as channels for ions (conduits or transporters) for salt and water across the ciliated membrane that lines the airways, the cystic fibrosis transmembrane conductance regulator or CFTR (the protein product of the CF gene, a chloride ion channel) and ENaC (the epithelial sodium ion channel), becomes very abnormal in this devastating disease of children and young adults.

Continue Reading »

DiscoveryBioMed, Inc. is awarded a new Phase 2 SBIR grant award to develop new medicines to fight the diabetes and obesity epidemic in the US and globally

DiscoveryBioMed, Inc. (DBM, Inc.) has learned in recent days that it has been awarded a $1.61M Phase 2 Small Business Innovation Research (SBIR) grant award from the National Institutes of Health and its National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) to develop novel ‘first in class’ small molecule drugs to fight multiple disease abnormalities caused by high blood sugar (hyperglycemia) and high blood fat such as metabolic syndrome, type 2 diabetes mellitus and obesity.

Continue Reading »